Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis

Diabetes and Metabolism

Volumn 45, Issue 2, 2019, Pages 102-109

  Mishriky, B M ^a   Cummings, D M ^a   Powell, J R ^a   Sewell, K A ^b   Tanenberg, R J ^b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1 receptor agonist; Meta analysis; Semaglutide; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; SEMAGLUTIDE; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; INCRETIN;

ACUTE PANCREATITIS; ADD ON THERAPY; BLOOD PRESSURE; BODY WEIGHT LOSS; CINAHL; COCHRANE LIBRARY; DIABETIC PATIENT; DIARRHEA; DOSAGE SCHEDULE COMPARISON; EMBASE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; REVIEW; SYSTEMATIC REVIEW; WEB OF SCIENCE; ADULT; ADVERSE EVENT; BLOOD; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85054531184     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2018.09.002     Document Type: Review

References (36)

1. Nauck, MA, Vilsboll, T, Gallwitz, B, Garber, A, Madsbad, S, Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 32:2 (2009), S223–S331.
2. Global guideline for type 2 diabetes. Diabetes Res Clin Pract 104 (2014), 1–52.
3. American Diabetes Association. 8 pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care 41:Suppl 1 (2018), S73–S85.
4. Garber, AJ, Abrahamson, MJ, Barzilay, JI, Blonde, L, Bloomgarden, ZT, Bush, MA, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2018 executive summary. Endocr Pract 24 (2018), 91–120.
5. Drucker, DJ, Nauck, MA, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
6. Meier, JJ, GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 (2012), 728–742.
7. Liberati, A, Altman, DG, Tetzlaff, J, Mulrow, C, Gotzsche, PC, Ioannidis, JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 6, 2009, e1000100.
8. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [update March 2011]. London, UK: The Cochrane Collaboration; 2011. Available from http://handbook.cochrane.org.
9. Jadad, AR, Moore, RA, Carroll, D, Jenkinson, C, Reynolds, DJ, Gavaghan, DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996), 1–12.
10. Mishriky, BM, Tanenberg, RJ, Sewell, KA, Cummings, DM, Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 44 (2018), 112–120.
11. Mishriky, BM, Cummings, DM, Tanenberg, RJ, The efficacy and safety of DPP-4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 109 (2015), 378–388.
12. Nauck, M, Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 18 (2016), 203–216.
13. Nauck, MA, Meier, JJ, Cavender, MA, Abd El Aziz, M, Drucker, DJ, Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation 136 (2017), 849–870.
14. Ahmann, AJ, Capehorn, M, Charpentier, G, Dotta, F, Henkel, E, Lingvay, I, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care 41 (2018), 258–266.
15. Ahren, B, Masmiquel, L, Kumar, H, Sargin, M, Karsbol, JD, Jacobsen, SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol 5 (2017), 341–354.
16. Nauck, MA, Petrie, JR, Sesti, G, Mannucci, E, Courreges, JP, Lindegaard, ML, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care 39 (2016), 231–241.
17. Pratley, RE, Aroda, VR, Lingvay, I, Ludemann, J, Andreassen, C, Navarria, A, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6 (2018), 275–286.
18. Seino, Y, Terauchi, Y, Osonoi, T, Yabe, D, Abe, N, Nishida, T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once-daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab 20 (2018), 378–388.
19. Nathan, DM, The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 37 (2014), 9–16.
20. Nathan, DM, Genuth, S, Lachin, J, Cleary, P, Crofford, O, Davis, M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 329 (1993), 977–986.
21. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.
22. Holman, RR, Paul, SK, Bethel, MA, Matthews, DR, Neil, HA, 10-year follow-up of intensive glucose control in type 2 diabetes. New Engl J Med 359 (2008), 1577–1589.
23. Bonnet, F, GLP-1 receptor agonist confer target organ protection in type 2 diabetes. Diabetes Metab 43:1 (2017), s1–s2.
24. Ryden, L, Shahim, B, Mellbin, L, Clinical implications of cardiovascular outcome trials in type 2 diabetes: from DCCT to EMPA-REG. Clin Ther 38 (2016), 1279–1287.
25. Pfeffer, MA, Claggett, B, Diaz, R, Dickstein, K, Gerstein, HC, Kober, LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. New Engl J Med 373 (2015), 2247–2257.
26. Marso, SP, Daniels, GH, Brown-Frandsen, K, Kristensen, P, Mann, JF, Nauck, MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New Engl J Med 375 (2016), 311–322.
27. Marso, SP, Bain, SC, Consoli, A, Eliaschewitz, FG, Jodar, E, Leiter, LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New Engl J Med 375 (2016), 1834–1844.
28. Holman, RR, Bethel, MA, Mentz, RJ, Thompson, VP, Lokhnygina, Y, Buse, JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. New Engl J Med 377 (2017), 1228–1239.
29. Scirica, BM, Braunwald, E, Raz, I, Cavender, MA, Morrow, DA, Jarolim, P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130 (2014), 1579–1588.
30. Zannad, F, Cannon, CP, Cushman, WC, Bakris, GL, Menon, V, Perez, AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
31. McGuire, DK, Van de Werf, F, Armstrong, PW, Standl, E, Koglin, J, Green, JB, et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol 1 (2016), 126–135.
32. Scheen, AJ, GLP-1 receptor agonists and cardiovascular protection: a class effect or not?. Diabetes Metab 44 (2018), 193–196.
33. Terrin, N, Schmid, CH, Lau, J, In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol 58 (2005), 894–901.
34. Terrin, N, Schmid, CH, Lau, J, Olkin, I, Adjusting for publication bias in the presence of heterogeneity. Stat Med 22 (2003), 2113–2126.
35. Thornton, A, Lee, P, Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 53 (2000), 207–216.
36. Kimura, T, Obata, A, Shimoda, M, Hirukawa, H, Kanda-Kimura, Y, Nogami, Y, et al. Durability of protective effect of dulaglutide on pancreatic beta-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure. Diabetes Metab 44 (2018), 250–260.